Aldafermin
Sponsors
NGM Biopharmaceuticals, Inc, Michael Camilleri, MD
Conditions
Bile Acid DiarrheaBile Acid MalabsorptionBile Acid Malabsorption Syndrome Type IIChronic DiarrheaCompensated CirrhosisFunctional DiarrheaHealthy MaleImpaired Hepatic Function
Phase 1
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
CompletedNCT04823702
Start: 2021-04-01End: 2021-11-19Updated: 2022-01-19
Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects
CompletedNCT04828265
Start: 2021-04-13End: 2021-07-06Updated: 2022-01-31
Phase 2
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
CompletedNCT04210245
Start: 2020-03-23End: 2023-02-23Updated: 2025-03-26
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
CompletedNCT05130047
Start: 2021-12-01End: 2022-11-08Updated: 2023-10-12
A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.
WithdrawnNCT06654726
Start: 2024-10-21End: 2025-03-18Updated: 2025-05-07